Across the recent three months, 19 analysts have shared their insights on Exelixis EXEL, expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 10 | 5 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 4 | 1 | 0 | 0 |
| 3M Ago | 1 | 6 | 3 | 0 | 0 |
Analysts have set 12-month price targets for Exelixis, revealing an average target of $32.53, a high estimate of $39.00, and a low estimate of $27.00. This upward trend is evident, with the current average reflecting a 10.27% increase from the previous average price target of $29.50.
Investigating Analyst Ratings: An Elaborate Study
An in-depth analysis of recent analyst actions unveils how financial experts perceive Exelixis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jason Gerberry | B of A Securities | Raises | Neutral | $39.00 | $35.00 |
| Michael Schmidt | Guggenheim | Raises | Buy | $33.00 | $32.00 |
| Sudan Loganathan | Stephens & Co. | Raises | Equal-Weight | $29.00 | $23.00 |
| Joseph Catanzaro | Piper Sandler | Raises | Overweight | $36.00 | $33.00 |
| Gregory Renza | RBC Capital | Maintains | Outperform | $34.00 | $34.00 |
| Asthika Goonewardene | Truist Securities | Raises | Buy | $38.00 | $33.00 |
| Derek Archila | Wells Fargo | Raises | Overweight | $36.00 | $32.00 |
| Etzer Darout | BMO Capital | Raises | Outperform | $36.00 | $29.00 |
| Yaron Werber | TD Cowen | Raises | Buy | $34.00 | $27.00 |
| Stephen Willey | Stifel | Raises | Hold | $30.00 | $26.00 |
| Gregory Renza | RBC Capital | Raises | Outperform | $34.00 | $30.00 |
| Silvan Tuerkcan | JMP Securities | Raises | Market Outperform | $34.00 | $29.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $32.00 | $30.00 |
| Silvan Tuerkcan | JMP Securities | Maintains | Market Outperform | $29.00 | $29.00 |
| Jefferson Harralson | Morgan Stanley | Raises | Equal-Weight | $28.00 | $26.00 |
| Gregory Renza | RBC Capital | Raises | Outperform | $30.00 | $27.00 |
| Gregory Renza | RBC Capital | Maintains | Outperform | $27.00 | $27.00 |
| Silvan Tuerkcan | JMP Securities | Maintains | Market Outperform | $29.00 | $29.00 |
| Ashwani Verma | UBS | Announces | Neutral | $30.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Exelixis's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
To gain a panoramic view of Exelixis's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Exelixis analyst ratings.
All You Need to Know About Exelixis
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Understanding the Numbers: Exelixis's Finances
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Exelixis displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 14.33%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exelixis's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.87% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Exelixis's ROE stands out, surpassing industry averages. With an impressive ROE of 5.37%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.12%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Exelixis adopts a prudent financial strategy, indicating a balanced approach to debt management.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
